跳至主要内容
临床试验/NCT01478269
NCT01478269已完成不适用

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

Fondazione Italiana Linfomi - ETS39 个研究点 分布在 2 个国家目标入组 1,927 人开始时间: 2009年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,927
试验地点
39

研究概览

简要总结

This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to
  • Any stage of disease.
  • Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
  • Age at least 18 years.
  • Availability of tissue biopsy at diagnosis for a possible centralized revision.
  • Availability of data on clinical involvement, laboratory, treatment and follow up.

排除标准

  • 未提供

研究者

申办方类型
Other
责任方
Sponsor

研究点 (39)

Loading locations...

相似试验

Prognosis Of Patients With Aggressive B-Cell... | 临床试验